Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Clinical trial NCT02684292 · COMPLETED
Trial details
- NCT number
- NCT02684292
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-23
- Primary completion
- 2026-01-14
- Enrollment
- 304
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.